Lipopolysaccharide (LPS) is a pathogenic factor that increases bone resorption in periodontal diseases. LPS treatment of osteoblasts was shown to induce the receptor activator of NF-κB ligand (RANKL), an essential secretory or membrane-bound factor for osteoclast function, in a manner dependent on extracellular signal-regulated kinase (ERK) activation. However, the mechanisms regulating this process remained unknown. Here, we show that RANKL mRNA induction and ERK activation, when treated with synthetic lipid A (an active center of LPS), were markedly reduced in mouse osteoblasts lacking Cot/Tpl2, which was recently recognized as an essential kinase for the induction of TNF-α by LPS in macrophages. In contrast, c-Jun N-terminal kinase (JNK), p38 kinase, Raf-1, and NF-κB were normally activated in cot/tpl2-/- osteoblasts. These findings indicate that Cot/Tpl2 is essential for LPS-induced ERK activation and RANKL induction in osteoblasts.
Get full access to this article
View all access options for this article.
References
1.
Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. -1997-. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature390:175–179.
2.
Belich MP, Salmeron A, Johnston LH, Ley SC -1999-. TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105. Nature397:363–368.
3.
Carson RE, Sayegh FS, Fedi PF Jr -1978-. Osteoclastic resorption of alveolar bone affected by periodontitis—correlation of light microscopic and scanning electron microscopic observations. J Periodontol49:406–414.
4.
Chiariello M, Marinissen MJ, Gutkind JS -2000-. Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol20:1747–1758.
5.
Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, et al. -2000-. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell103:1071–1083.
6.
Fuller K, Wong B, Fox S, Choi Y, Chambers TJ -1998-. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med188:997–1001.
7.
Guthridge CJ, Eidlen D, Arend WP, Gutierrez-Hartmann A, Smith MF Jr -1997-. Lipopolysaccharide and Raf-1 kinase regulate secretory interleukin-1 receptor antagonist gene expression by mutually antagonistic mechanisms. Mol Cell Biol17:1118–1128.
8.
Higashi T, Sasai H, Suzuki F, Miyoshi J, Ohuchi T, Takai S, et al. -1990-. Hamster cell line suitable for transfection assay of transforming genes. Proc Natl Acad Sci USA87:2409–2413.
9.
Kikuchi T, Matsuguchi T, Tsuboi N, Mitani A, Tanaka S, Matsuoka M, et al. -2001-. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. J Immunol166:3574–3579.
10.
Kitazawa R, Kitazawa S, Maeda S -1999-. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim Biophys Acta1445:134–141.
11.
Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. -1999-. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature397:315–323.
12.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. -1998-. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell93:165–176.
13.
Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM -2000-. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem275:20959–20962.
14.
Miyoshi J, Higashi T, Mukai H, Ohuchi T, Kakunaga T -1991-. Structure and transforming potential of the human cot oncogene encoding a putative protein kinase. Mol Cell Biol11:4088–4096.
15.
Monick MM, Carter AB, Flaherty DM, Peterson MW, Hunninghake GW -2000-. Protein kinase C zeta plays a central role in activation of the p42/44 mitogen-activated protein kinase by endotoxin in alveolar macrophages. J Immunol165:4632–4639.
16.
Patriotis C, Makris A, Bear SE, Tsichlis PN -1993-. Tumor progression locus 2 -Tpl-2- encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci USA90:2251–2255.
17.
Patriotis C, Makris A, Chernoff J, Tsichlis PN -1994-. Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase. Proc Natl Acad Sci USA91:9755–9759.
18.
Salmeron A, Ahmad TB, Carlile GW, Pappin D, Narsimhan RP, Ley SC -1996-. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J 15:817–826.
19.
Schletter J, Heine H, Ulmer AJ, Rietschel ET -1995-. Molecular mechanisms of endotoxin activity. Arch Microbiol164:383–389.
20.
Suda K, Woo JT, Takami M, Sexton PM, Nagai K -2002-. Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL. J Cell Physiol190:101–108.
21.
Sweet MJ, Hume DA -1996-. Endotoxin signal transduction in macrophages. J Leukoc Biol60:8–26.
22.
Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, et al. -1988-. Osteoblastic cells are involved in osteoclast formation. Endocrinology123:2600–2602.
23.
Widmann C, Gibson S, Jarpe MB, Johnson GL -1999-. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev79:143–180.
24.
Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, et al. -1997a-. TRANCE -tumor necrosis factor [TNF] -related activation-induced cytokine-, a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med186:2075–2080.
25.
Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. -1997b-. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem272:25190–25194.
26.
Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, et al. -1999-. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell4:1041–1049.
27.
Xiao Q, Jiang D, Thomas P, Benson MD, Guan K, Karsenty GS, et al. -2000-. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem275:4453–4459.
28.
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. -1998-. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA95:3597–3602.
